From psychiatric disorders to animal models: a bidirectional and dimensional approach

Zoe. R. Donaldson and **René Hen**[*]

Departments of Psychiatry and Neuroscience, Columbia University andDivision of Integrative Neuroscience, New York State Psychiatric Institute, New York, NY 10032

Abstract

Psychiatric genetics research is bidirectional in nature, with human and animal studies becoming more closely integrated as techniques for genetic manipulations allow for more subtle exploration of disease phenotypes. This synergy, however, highlights the importance of considering the way in which we approach the genotype-phenotype relationship. In particular, the nosological divide of psychiatric illness, while clinically relevant, is not directly translatable in animal models. For instance, mice will never fully re-capitulate the broad criteria for many psychiatric disorders; nor will they have guilty ruminations, suicidal thoughts, or rapid speech. Instead, animal models have been and continue to provide a means to explore dimensions of psychiatric disorders in order to identify neural circuits and mechanisms underlying disease-relevant phenotypes. Thus, the genetic investigation of psychiatric illness will yield the greatest insights if efforts continue to identify and utilize biologically valid phenotypes across species. In this review we discuss the progress to date and the future efforts that will enhance translation between human and animal studies, including the identification of intermediate phenotypes that can be studied across species, as well as the importance of refined modeling of human disease-associated genetic variation in mice and other animal models.

Keywords

intermediate phenotype; BDNF; serotonin; dentate gyrus; pattern separation; amygdala; anxiety

Bidirectional nature of genetics research

Our understanding of behavioral disorders has benefited from the reciprocal nature of genetic research in humans and animal models. Animal models remain an important tool for

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

studying the functional role of human mutations, and basic animal research has driven studies of candidate genetic variation in humans. Within the realm of behavioral disorders, numerous examples of the back-and-forth between human and animal research already exist, but as will be discussed later in this review, a refinement of the way we approach disease-related phenotypes, combined with more subtle genetic techniques, will help strengthen this translational interplay.

One area of research that began in animal models and has since garnered substantial interest in human research has been the role of the so-called "social" neuropeptides, oxytocin and vasopressin, and their potential role in human social behaviors (1). Initial work in animal models revealed a conserved role for these peptides in the modulation of social behavior (2). Mice with null mutations in the genes encoding either oxytocin (OT) or the V1a vasopressin receptor subtype (V1aR) lack the ability to remember a previously encountered conspecific, a memory deficit that is specific for social cues (3, 4). In addition, OT and vasopressin (AVP) play a critical role in the formation and maintenance of pair bonds in monogamous prairie voles (5). In mice, which are not monogamous, oxytocin is also required for social reward (6). Given that many psychiatric conditions and behavioral disorders include strong social components, such as the profound social deficits observed in autism and schizophrenia, these animal studies have spurred research on the function and potential contribution of these genes and their receptors in humans (7). Specifically, genetic variation within the loci that encode these neuropeptides and their receptors has been tied to differences in diverse, socially relevant traits, and nominally, with autism (8). Much of the work on OT suggests that it may be involved in complex social abilities in humans (9); intranasal oxytocin increases trust, in particular contexts, and also heightens a subject's ability to accurately infer emotional states of others (10–12). In addition, two SNPs in the oxytocin receptor gene (rs53576A and rs2254298A) have emerged as genetic candidates for social deficits in humans, such as decreased maternal sensitivity and empathy (13, 14). Intriguingly, in work that parallels findings in prairie voles, a variant of the human AVP receptor gene, *AVPR1A*, has been associated with differences in human pair bonding, with variant RS3-334 associated with decreased relationship quality (15).

The converse also occurs. Animal models have been especially relevant for validating and exploring highly penetrant, rare genetic mutations identified via family pedigrees or population studies. For instance, sequencing of exons in serotonergic and dopaminergic genes in highly impulsive individuals in a Finnish founder population revealed a mutation that introduces a stop codon in the serotonin 2B (5HT2B) receptor gene (16). A critical piece of evidence supporting the functional contribution of this mutation came from 5HT2B knockout mice, which also display increased impulsive behaviors (16). Equally informative, if not more so, are the occasions when a knockout mouse fails to recapitulate human disease phenotypes. For instance, Lesch-Nyhan Syndrome is a rare X-linked developmental disorder resulting from mutations in the hypoxanthine phosphoribosyltransferase gene (*HPRT*), which leads to a buildup of uric acid and results in neurological phenotypes including uncontrolled writhing, repetitive movements, and self-injurious behaviors. However, knockout of the mouse *Hprt* gene does not result in the profound phenotypes observed in humans (17, 18). Instead, comparative genetic studies revealed that the phenotypic disparity

between mice and humans is likely due to phosphoribosyltransferase domain containing 1 gene (*PRTFDC1*), a paralog of *HPRT* that is a functional gene in humans but an inactivated pseudogene in mice (19). BAC transgenic mice with a functional human copy of *PRTFDC1* and mutant *Hprt* demonstrated increased aggression and amphetamine-induced stereotypies, reminiscent of the symptoms of Lesch-Nyhan Syndrome. This suggests that *PRTFC1* is an important genetic modifier of *HPRT* deficiency and provides important implications for unraveling the molecular etiology of Lesch-Nyhan Syndrome (20).

There is a clear mutualistic relationship between these research disciplines. Yet despite this, the experiments pursued by human/clinical researchers and basic researchers working in animal models are often not directly translatable for both conceptual and technical reasons. For instance, experiments on the role of social neuropeptides in monogamy and social recognition in rodent models relate broadly but nonspecifically to their potential role in empathy, maternal attentiveness, and autism in humans. Thus, it is difficult to hypothesize a shared mechanism or clinically-relevant intervention from these dual lines of research. In addition, knockout mice are technically poor models for understanding the potentially complex effects of common genetic variants. Thus, this review will focus on improving conceptual translatability by studying the same intermediate phenotypes in both humans and animals and will highlight transgenic strategies in animal models that more directly model human genetic variation, improving their clinical relevance.

Improving translatability through intermediate phenotypes

It has largely been acknowledged by the research community that there is limited biological validity underlying the current classification of psychiatric illness. For instance, based on DSM guidelines, opposite symptoms can characterize the same disorder, while many other symptoms are shared across disorders. Both fatigue/decreased energy and increased agitation/restlessness are considered symptoms of depression (21), while altered sleep patterns, mood dysregulation, and cognitive changes transcend diagnostic categories. Underscoring the idea that nosologically distinct disorders have mutual biological underpinnings, a recent large scale genetic study found that five disorders - schizophrenia, bipolar disorder, autism, depression, and attention-deficit disorder – share common genetic risk factors (22). Notably, this parallels what is known about the genetics of autoimmune disorders where a handful of genetic variants have been implicated in multiple disorders (23, 24).

Given these facts, a number of approaches have been proposed for studying the biological underpinnings of psychiatric disorders in a way that accommodates potentially shared biological mechanisms and the diversity of symptomology observed in psychiatric illness. Among the earliest of these, in 1967, Gottesman and Shield introduced to psychiatry the term "endophenotype," from the Greek "endos," meaning interior, which they adopted from a report on evolutionary biology (25). The original definition of an endophenotype required meeting several criteria including having sufficient heritability, showing increased expression in unaffected relatives of probands, cosegregating with a disorder in a family, being stable over time, and having good psychometric properties (26). This "bottom-up"

approach for studying the neural basis of psychiatric illness, has become nearly synonymous with breaking down psychological disorders and processes into biologically mechanisms.

More recently, there has also been a top-down push by some psychiatrists to adopt a dimensional approach to diagnostic criteria, which was proposed but ultimately not adopted in DSM5 (27). This approach acknowledges the symptom overlap of many disorders and proposes that they are the product of shared risk factors that drive abnormalities in behavioral spectra, such as motivation and reward anticipation. This concept of dimensions mirrors the logic underlying the NIMH Research Domain Criteria (RDoC) initiative, which posits that mental illness will be best understood as disorders of brain structure and function that implicate specific domains of cognition, emotion, and behavior (27, 28). Thus, current NIMH research is focused on identifying new dimensions, such as pattern separation and social recognition (see below), suitable for research on the genetic and biological basis of psychiatric illness.

In addition to these bottom-up and top-down approaches, more recent debates have also suggested the use of a third, potentially unifying term of "intermediate phenotype," which we will use throughout this paper. This term has a number of advantages. Analogous to its usage in other areas of complex genetics, it implies that a trait is in a predictable path from gene to disease. Further, intermediate phenotypes are not restricted by the stringent criteria used to define endophenotypes. And finally, the intermediate phenotypes we discuss in this review include both biological and behavioral phenotypes, bridging a potential conceptual divide between endophenotype and dimensional approaches. Because many of these phenotypes exist in both animal models and humans, there is a substantially enhanced opportunity for translation by focusing on intermediate phenotypes rather than disease categories.

Impaired pattern separation and dentate gyrus function: examples of behavioral and neural intermediate phenotypes

Both human and animal studies support the fact that a region of the hippocampus, the dentate gyrus (DG), is essential for pattern separation during memory encoding. Pattern separation is a process by which similar experiences or events are transformed into discrete non-overlapping representations (29, 30), and represents a behavioral intermediate phenotype. Experimental evidence for a role of the DG in pattern separation first came from lesion studies in rodents showing that ablation of the DG impaired discrimination of two spatial locations based on distal environmental cues (31). More recent studies relying on genetic approaches to specifically manipulate DG functions have yielded similar results (32), and multi-tetrode recordings have shown that subtle morphing of a rat's environment is sufficient to elicit remapping of firing rates of place cells in the DG, suggesting that small changes in spatial input can produce highly divergent output (29). Collectively, these studies suggest that the DG is required to minimize interference between overlapping spatial or contextual information. Neurocognitive testing and fMRI studies in humans have also suggested a role for the DG in pattern separation (33, 34); high-resolution functional imaging studies have detected specific changes in activity in the DG/CA3 circuit during a pattern separation task. Thus DG function represents a neural intermediate phenotype.

According to the theory (35), impaired pattern separation is the consequence of DG malfunction and leads to excessive generalization, causing an organism to group multiple contexts or items together even if they are dissimilar. Such a maladaptive response may contribute to the generalization of previously encountered aversive events to new "innocuous" experiences as seen in individuals with panic disorder and PTSD (36–38). For example, for someone who developed PTSD as a result of 9/11, the sight of a plane flying over New York City may trigger flashbacks and panic. Impaired pattern separation has also been reported during aging and in individuals with mild cognitive impairment (MCI). Deficits in pattern separation and DG function may represent important intermediate phenotypes for these different disorders and contribute to some of their associated impairments. As we have shown that increasing adult hippocampal neurogenesis in animal models improves pattern separation (39), we hypothesize that increasing human hippocampal neurogenesis may improve pattern separation-related impairments in individuals with MCI or anxiety disorders.

This is an example where translation works from animals to humans; a brain region was identified in rodents that mediates pattern separation (the dentate gyrus); this triggered human investigations aimed at identifying patients with pattern separation deficits as well as dentate gyrus dysfunction (33). In turn, these patients become candidates for pharmacological interventions aimed at improving pattern separation, such as compounds that stimulate dentate gyrus neurogenesis (40).

Genetics of intermediate phenotypes

The rate-limiting factor in identifying gene variants related to disease is often the effect size of the risk allele on phenotypic variance. Because genes do not encode psychiatric phenomena, but instead encode gene products that influence the circuits underlying a behavior, genetic variation should have enhanced penetrance at the level of quantitative intermediate phenotypes, such as circuit function or even discrete behavioral traits. Further, the genetic architecture of such phenotypes is hypothesized to be simplified compared to that of the disease itself. Both biological and behavioral intermediate phenotypes support these assumptions.

At a biological level, the field of imaging genetics has demonstrated that so-called psychiatric risk alleles are more closely tied to variance on a brain systems level as compared with clinical diagnoses (41). For instance, a polymorphism in the promoter of the serotonin transporter gene promoter (5-HTTLPR) accounts for up to 10% of variance in amygdala activation (42), whereas its role in predicting behavioral phenotypes such as neuroticism, depression, or antidepressant response is at least an order of magnitude lower, likely ranging around 1 – 3% (43–48).

Behaviorally, it has also been shown that relatively simple traits display stronger genetic associations than do diseases *per se*. As previously mentioned, oxytocin and vasopressin are required for normal social recognition in rodents (49). Using social recognition as an intermediate phenotype, a recent study found that a SNP near the oxytocin receptor (rs237887) was strongly associated with social recognition memory in families with one

high functioning autistic child (50). This SNP accounted for 10% of the variation in test performance but failed to reach significance when associated with autism diagnosis, mirroring the mixed reports of oxytocin/autism associations in the literature. A similar trend was seen for variation in the vasopressin receptor 1a gene. This finding is particularly striking because mice and humans use different modalities (olfactory versus visual) as a primary means of social recognition, suggesting that the physiological underpinnings of social recognition have remained evolutionarily conserved across perceptual boundaries and further supporting the use of such intermediate phenotypes as a way to enhance translational analyses.

Despite the potential utility of intermediate phenotypes, the majority of large-scale genetic associations to date have been undertaken based on categorical diagnoses. Thus, the majority of the associations that have been reported in the literature have been gene-disease associations. These genetic variants then become candidates for further study at the level of intermediate phenotype in order to identify biological mechanisms underlying disease states. However, by investigating the genetics of intermediate phenotypes beyond a priori candidate genes, we may gain insight into genes that are important for disease but have an effect size that is too small to detect in traditional disease-gene association studies. Further, because intermediate phenotypes are independent of disease diagnoses, and may span multiple disorders, they may point to unique pharmacological targets that could be effective across disorders, in much the same way that selective serotonin reuptake inhibitors (SSRIs) are currently used pan-categorically. Alternatively, the panoply of intermediate mediates and brain circuits disrupted may be specific to a particular population, and a personalized multi-drug approach based on treatment of intermediate phenotypes may be warranted.

The same intermediate phenotype approach should be applied to models of drug responsiveness, and their underlying genetic factors. Current therapeutics, such as SSRIs have myriad behavioral and biological affects, including decreased immobility in the forced swim test (51), increased hippocampal neurogenesis (52), and re-regulation of the hypothalamic-pituitary axis (53, 54). It is not clear which of these many effects are responsible for the antidepressant effects of these medications. An intermediate phenotype approach would consist of studying these effects in isolation; for example, what is the impact of stimulating neurogenesis on behavior? Our work suggests one of the main effects in baseline conditions is to improve pattern separation, and in some conditions, to decrease anxiety (39). One could therefore use neurogenesis as a screen for novel therapies aimed at specific populations that display a pattern separation deficit. Such a population would have to be characterized based on a combination of behavioral tests (55) and possibly imaging modalities that still need to be developed (56). Identifying the role of genetic variation within drug-responsive intermediate phenotypes would provide an additional level of potential treatment precision and insight into individual differences in drug efficacy.

Utility of mouse models to identify mechanisms underlying intermediate phenotypes

Consistent with the idea that different disorders may be influenced by shared underlying intermediate phenotypes, brain derived neurotrophic factor (BDNF) has been widely implicated in a range of psychiatric conditions, including but not limited to major depressive

disorder, schizophrenia, addiction, Rett syndrome, and eating disorders (57). BDNF has broad ranging roles in axon targeting, neuron growth, maturation of synapses, and synaptic plasticity. Further, BDNF levels are altered by stress exposure and display complex interactions with sex steroids (57). This presents multiple potential mechanisms by which this molecule can affect disease-related traits both directly and via interactions with environmental or hormonal modulators.

To date, numerous mouse models have been developed better understand the role of BDNF in various intermediate phenotypes (57, 58). However, the most relevant demonstration of the importance of animal models for studying intermediate phenotypes and their genetic underpinnings comes from a mouse model of a common variant in the BDNF gene, Val66Met. In the human population, a common SNP in the *BDNF* coding region is found in 20 – 30% of the Caucasian population (59) and leads to a methionine substitution for valine at codon 66 (Val66Met). A meta-analysis confirms that the Met allele is associated with decreased hippocampal volumes (60). Hippocampal volume and function represent intermediate phenotypes that are sensitive to anti-depressant treatment (61–64), and have been implicated in a number of disorders, including major depressive disorder (65, 66), PTSD (67), anxiety disorders (38), and schizophrenia (68).

BDNF Val66Met has been modeled in mice by introducing this mutation into the endogenous mouse *Bdnf* gene, which has proven to be a particularly powerful translational approach. The Met allele in mice leads to a 30% reduction in activity dependent release of BDNF, although expression levels are not altered (69). In addition, hippocampal volume is decreased in Met mice, and neurons in the dentate gyrus show decreased dendritic complexity. Behaviorally, Met-allele mice show decreased freezing in contextual fear conditioning, a hippocampal-dependent phenotype, and also show increased levels of anxiety. Further, Met, but not Val, mice are insensitive to the anxiolytic effects of SSRIs (69). Parallel experiments also demonstrated that Met-allele carrying mice and humans both show reductions in extinction learning when a neutral cue was paired with an aversive stimulus, an intermediate phenotype that may be relevant to therapeutic interventions that include an extinction component.

One of the most valuable aspects of this model is that, having been clearly linked to intermediate phenotypes important for psychiatric illness, it enables a mechanistic investigation of these phenotypes in a way that cannot be pursued in humans. This includes invasive assessments of neuronal attributes, gene expression, and neurophysiology. For example, recent work has demonstrated that the Met66 prodomain is structurally different from its Val66 counterpart, and that it is secreted at lower levels from hippocampal neurons in culture (70). Further it was shown that Met66 prodomain (but not Val66) modulates neuronal morphology through growth cone retraction, potentially explaining the decreased hippocampal size associated with the Met allele. In addition, Met-allele humans also displayed increased amygdala activity and decreased activity in the ventromedial prefrontal cortex (vmPFC) during cue presentation, which may indicate better vmPFC modulation of amygdala activity in Val/Val individuals (71). Work in Bdnf Val66Met mice provides a putative mechanism for this by demonstrating that spike timing-dependent plasticity is absent in the infralimbic-mPFC of Met/Met mice and that Met/Met mice also display

reduced NMDA and GABA-receptor mediated transmission in pyramidal neurons (72). Finally, Met/Met mice also display decreased anti-depressant responsiveness at a behavioral level. Potenially underlying this, Met/Met mice fail to increase Bdnf levels following treatment with fluoxetine and also fail to show fluoxetine-induced enhancements in hippocampal synaptic plasticity (73). It is worth noting that Bdnf knockout models largely could not have been used to reveal the above mechanisms, highlighting the importance of generating a model of the human disease-associated genetic variant itself. Thus, the clear translational utility of BDNF and other direct genetic models, such as the 5-HTT Ala56 mouse (74), have revealed a pressing need for additional direct models of genetic variation in mice.

One area where such "humanized" models would provide significant advances and clarification is in the role of serotonergic variation. Serotonergic systems have been broadly implicated in diverse psychiatric disorders, and drugs that impact this system, including SSRIs, are the most commonly prescribed pharmacotherapies for many disorders. Of particular note, a VNTR in the gene encoding 5-HTT (*5-HTTLPR*) has been extensively implicated in disease-related phenotypes. This polymorphism, which occurs in the regulatory region for 5-HTT, is related to differences in 5-HTT levels in human cell lines (75), and has been associated with both anxiety and depression, although these findings, along with evidence that the short (S) allele may be more environmentally reactive have been inconsistent in human studies (42, 43, 45, 46, 76). However, the largest meta-analysis performed to date reports a significant association between the S allele and depression in individuals exposed to early life traumas (45), highlighting the importance of gene-environment interactions.

Given the variable reports of associations in human studies, imaging studies linking intermediate phenotypes and 5-HTTLPR have been employed based on the assumption that brain activation patterns would be a more reliable readout of genotype effects than complex clinical diagnoses. MRI studies investigating the relationship between 5-HTTLPR and amygdala activity have shown that healthy S allele carriers have higher levels of amygdala activity as compared to individuals homozygous for the long allele(42), In addition, 5HTTLPR has also been linked to differences in the amygdala-anterior cingulate cortex circuit, with S allele carriers demonstrating reductions of functional coupling (41).

Both primate and mouse models broadly support the involvement of 5-HTT variation in disease-relevant phenotypes. Rhesus macaques have a similar VNTR in their own gene and a substantial literature suggests that the S allele confers increased stress-responsiveness, enhancing alcohol sensitivity (77) and other behavioral anomalies in animals raised in a stressful environment (78). In addition, mice heterozygous for *SLC6A4*, the gene that encodes 5-HTT, which have 5-HTT levels approximately 50% lower than wildtype mice, have also been proposed as a model for the S allele (79). *SLC6A4* heterozygotes show enhanced vulnerability to psychosocial stress, displaying increased suppression of locomotor activity and social avoidance (80). However, in many instances the 5HTT-linked phenotypes studied in humans and in animal models are not identical, and without transparent comparison of intermediate phenotypes across species or a direct model of 5-HTTLPR in mice, the translation of these findings is somewhat confounded.

In addition to variation in the transporter, significant efforts have also focused on the inhibitory receptor, serotonin receptor 1A (5-HT1A), which regulates the firing of serotonergic raphe neurons, impacting serotonin levels at projection sites throughout the brain. Within this system, genetic techniques have been particularly important for parsing the role of 5-HT1A in both anxiety and depression-related phenotypes. 5-HT1A null mutant mice demonstrate a complex phenotype that includes increased anxiety, increased stress-coping, and decreased antidepressant responsiveness (81, 82). Mouse models enabling both spatial and temporal control of the 5-HT1A receptor have implicated different receptor populations and developmental phases in these diverse phenotypes. Specifically, post-natal suppression of 5-HT1A levels selectively in the raphe led to increased anxiety without affecting stress-reactivity (83). Conversely, adult suppression of raphe receptor levels did not affect anxiety, but did increase stress resiliency and antidepressant responsiveness, a finding independently confirmed through the use of siRNAs to decrease adult 5-HT1A levels in the raphe (84, 85).

These findings have been proposed as a model for rs6295, a common promoter polymorphism in the human HTR1A gene. The G allele of this SNP has been linked to increased risk of suicide, incidence of depression, and decreased anti-depressant responsiveness (86). This allele fails to bind the transcriptional repressor, Deaf-1, in cell lines derived from raphe neurons, leading to increased transcription (87) and is associated with higher 5-HT1A binding potential in G-allele carriers (88). Future efforts to develop a humanized mouse model of this polymorphism will be integral to identifying its direct and complex effects on both biological and behavioral intermediate phenotypes, as well as their underlying mechanisms.

Moving forward

As psychiatry and neuroscience converge, intermediate phenotypes, especially combined with novel transgenic techniques, will facilitate translational investigation. These approaches may have particular value for investigating, at a circuit level, the ways in which genes and the environment interact to shape behavioral phenotypes and predisposition to psychiatric illness. However, while the intermediate phenotype approach has face validity at a conceptual level, there are a number of important questions relevant for the field of psychiatry that will only be answered by scientific and medical advances. Among the most pressing is how treatments designed to alter intermediate phenotypes will be best used to treat psychiatric illness. Indeed, we may be moving toward a more personalized approach where patients will be first stratified based on a series of intermediate phenotypes and then treated with a cocktail of drugs targeting these specific phenotypes.

References

1. Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010; 65:768–779. [PubMed: 20346754]

2. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science. 2008; 322:900–904. [PubMed: 18988842]

3. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004; 29:483–493. [PubMed: 14647484]

4. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet. 2000; 25:284–288. [PubMed: 10888874]

5. Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm Behav. 2006; 50:506–517. [PubMed: 16890230]

6. Dolen G, Darvishzadeh A, Huang KW, Malenka RC. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature. 2013; 501:179–184. [PubMed: 24025838]

7. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature Reviews Neuroscience. 2011; 12:524–538.

8. Ebstein RP, Knafo A, Mankuta D, Chew SH, Lai PS. The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav. 2012; 61:359–379. [PubMed: 22245314]

9. Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Frontiers in Neuroendocrinology. 2011; 32:426–450. [PubMed: 21802441]

10. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mind-reading" in humans. Biological Psychiatry. 2007; 61:731–733. [PubMed: 17137561]

11. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. Oxytocin Shapes the Neural Circuitry of Trust and Trust Adaptation in Humans. Neuron. 2008; 58:639–650. [PubMed: 18498743]

12. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005; 435:673–676. [PubMed: 15931222]

13. Bakermans-Kranenburg MJ, van Ijzendoorn MH. Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting. Social cognitive and affective neuroscience. 2008; 3:128–134. [PubMed: 19015103]

14. Tost H, Kolachana B, Hakimi S, Lemaitre H, Verchinski BA, Mattay VS, et al. A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. Proc Natl Acad Sci U S A. 2010; 107:13936–13941. [PubMed: 20647384]

15. Walum H, Westberg L, Henningsson S, Neiderhiser JM, Reiss D, Igl W, et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci U S A. 2008; 105:14153–14156. [PubMed: 18765804]

16. Bevilacqua L, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T, et al. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature. 2010; 468:1061–1066. [PubMed: 21179162]

17. Engle SJ, Womer DE, Davies PM, Boivin G, Sahota A, Simmonds HA, et al. HPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome. Hum Mol Genet. 1996; 5:1607–1610. [PubMed: 8894695]

18. Finger S, Heavens RP, Sirinathsinghji DJ, Kuehn MR, Dunnett SB. Behavioral and neurochemical evaluation of a transgenic mouse model of Lesch-Nyhan syndrome. J Neurol Sci. 1988; 86:203–213. [PubMed: 3221240]

19. Keebaugh AC, Sullivan RT, Thomas JW. Gene duplication and inactivation in the HPRT gene family. Genomics. 2007; 89:134–142. [PubMed: 16928426]

20. Keebaugh AC, Mitchell HA, Gaval-Cruz M, Freeman KG, Edwards GL, Weinshenker D, et al. PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse. PLoS One. 2011; 6:e22381. [PubMed: 21818316]

21. Association AP. Diagnostic and statistical manual of mental disorders. 5. Arlington, VA: American Psychiatric Publishing; 2013.

22. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381:1371–1379. [PubMed: 23453885]

23. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011; 7:e1002254. [PubMed: 21852963]

24. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011; 7:e1002004. [PubMed: 21383967]

25. Gottesman, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A. 1967; 58:199–205. [PubMed: 5231600]

26. Gottesman, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003; 160:636–645. [PubMed: 12668349]

27. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013; 11:126. [PubMed: 23672542]

28. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167:748–751. [PubMed: 20595427]

29. Leutgeb JK, Leutgeb S, Moser MB, Moser EI. Pattern separation in the dentate gyrus and CA3 of the hippocampus. Science (New York, NY. 2007; 315:961–966.

30. Treves A, Tashiro A, Witter ME, Moser EI. What is the mammalian dentate gyrus good for? Neuroscience. 2008; 154:1155–1172. [PubMed: 18554812]

31. Gilbert PE, Kesner RP, Lee I. Dissociating hippocampal subregions: double dissociation between dentate gyrus and CA1. Hippocampus. 2001; 11:626–636. [PubMed: 11811656]

32. McHugh TJ, Jones MW, Quinn JJ, Balthasar N, Coppari R, Elmquist JK, et al. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science. 2007; 317:94–99. [PubMed: 17556551]

33. Bakker A, Kirwan CB, Miller M, Stark CE. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008; 319:1640–1642. [PubMed: 18356518]

34. Lacy JW, Yassa MA, Stark SM, Muftuler LT, Stark CE. Distinct pattern separation related transfer functions in human CA3/dentate and CA1 revealed using high-resolution fMRI and variable mnemonic similarity. Learn Mem. 2010; 18:15–18. [PubMed: 21164173]

35. Marr D. Simple memory: a theory for archicortex. Philos Trans R Soc Lond B Biol Sci. 1971; 262:23–81. [PubMed: 4399412]

36. Lissek S, Rabin S, Heller RE, Lukenbaugh D, Geraci M, Pine DS, et al. Overgeneralization of conditioned fear as a pathogenic marker of panic disorder. Am J Psychiatry. 2010; 167:47–55. [PubMed: 19917595]

37. Peri T, Ben-Shakhar G, Orr SP, Shalev AY. Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder. Biological psychiatry. 2000; 47:512–519. [PubMed: 10715357]

38. Kheirbek MA, Klemenhagen KC, Sahay A, Hen R. Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders. Nat Neurosci. 2012; 15:1613–1620. [PubMed: 23187693]

39. Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, et al. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 2011; 472:466–470. [PubMed: 21460835]

40. Sahay A, Wilson DA, Hen R. Pattern separation: a common function for new neurons in hippocampus and olfactory bulb. Neuron. 2011; 70:582–588. [PubMed: 21609817]

41. Scharinger C, Rabl U, Pezawas L, Kasper S. The genetic blueprint of major depressive disorder: contributions of imaging genetics studies. World J Biol Psychiatry. 2011; 12:474–488. [PubMed: 21830992]

42. Munafo MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biological Psychiatry. 2008; 63:852–857. [PubMed: 17949693]

43. Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B:271–281. [PubMed: 18546120]

44. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry. 2007; 12:247–257. [PubMed: 17146470]

45. Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. 2011; 68:444–454. [PubMed: 21199959]

46. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA : the journal of the American Medical Association. 2009; 301:2462–2471. [PubMed: 19531786]

47. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2013; 45:183–194. [PubMed: 23733030]

48. Clarke H, Flint J, Attwood AS, Munafo MR. Association of the 5- HTTLPR genotype and unipolar depression: a meta-analysis. Psychological medicine. 2010; 40:1767–1778. [PubMed: 20380781]

49. Bielsky IF, Young LJ. Oxytocin, vasopressin, and social recognition in mammals. Peptides. 2004; 25:1565–1574. [PubMed: 15374658]

50. Skuse DH, Lori A, Cubells JF, Lee I, Conneely KN, Puura K, et al. Common polymorphism in the oxytocin receptor gene (OXTR) is associated with human social recognition skills. Proc Natl Acad Sci U S A. 2013

51. Bourin M, Colombel MC, Redrobe JP, Nizard J, Hascoet M, Baker GB. Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Progress in neuro-psychopharmacology & biological psychiatry. 1998; 22:343–351. [PubMed: 9608606]

52. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron. 2009; 62:479–493. [PubMed: 19477151]

53. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl). 2001; 156:73–78. [PubMed: 11465636]

54. Jensen JB, Jessop DS, Harbuz MS, Mork A, Sanchez C, Mikkelsen JD. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. Journal of Neuroendocrinology. 1999; 11:465–471. [PubMed: 10336728]

55. Stark SM, Yassa MA, Lacy JW, Stark CE. A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment. Neuropsychologia. 2013; 51:2442–2449. [PubMed: 23313292]

56. Sierra A, Encinas JM, Maletic-Savatic M. Adult human neurogenesis: from microscopy to magnetic resonance imaging. Front Neurosci. 2011; 5:47. [PubMed: 21519376]

57. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012; 64:238–258. [PubMed: 22407616]

58. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biological Psychiatry. 2006; 59:1116–1127. [PubMed: 16631126]

59. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev. 2004; 45:104–114. [PubMed: 15145621]

60. Molendijk ML, Bus BA, Spinhoven P, Kaimatzoglou A, Oude Voshaar RC, Penninx BW, et al. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume--a genuine effect or a winners curse? Am J Med Genet B Neuropsychiatr Genet. 2012; 159B:731–740. [PubMed: 22815222]

61. Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013; 52:75–83. [PubMed: 22659303]

62. Castren E. Neurotrophic effects of antidepressant drugs. Current Opinion in Pharmacology. 2004; 4:58–64. [PubMed: 15018840]

63. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007; 10:1110–1115. [PubMed: 17726477]

64. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology. 2007; 18:391–418. [PubMed: 17762509]

65. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000; 157:115–118. [PubMed: 10618023]

66. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 2004; 161:598–607. [PubMed: 15056502]

67. Smith ME. Bilateral hippocampal volume reduction in adults with post-traumatic stress disorder: a meta-analysis of structural MRI studies. Hippocampus. 2005; 15:798–807. [PubMed: 15988763]

68. Adriano F, Caltagirone C, Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. 2012; 18:180–200.

69. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006; 314:140–143. [PubMed: 17023662]

70. Anastasia A, Deinhardt K, Chao MV, Will NE, Irmady K, Lee FS, et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun. 2013; 4:2490. [PubMed: 24048383]

71. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science. 2010; 327:863–866. [PubMed: 20075215]

72. Pattwell SS, Bath KG, Perez-Castro R, Lee FS, Chao MV, Ninan I. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J Neurosci. 2012; 32:2410–2421. [PubMed: 22396415]

73. Bath KG, Jing DQ, Dincheva I, Neeb CC, Pattwell SS, Chao MV, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2012; 37:1297–1304. [PubMed: 22218094]

74. Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci U S A. 2012; 109:5469–5474. [PubMed: 22431635]

75. Heils A, Mossner R, Lesch KP. The human serotonin transporter gene polymorphism--basic research and clinical implications. Journal of Neural Transmission. 1997; 104:1005–1014. [PubMed: 9503253]

76. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003; 301:386–389. [PubMed: 12869766]

77. Barr CS, Newman TK, Lindell S, Shannon C, Champoux M, Lesch KP, et al. Interaction between serotonin transporter gene variation and rearing condition in alcohol preference and consumption in female primates. Arch Gen Psychiatry. 2004; 61:1146–1152. [PubMed: 15520362]

78. Lesch KP, Meyer J, Glatz K, Flugge G, Hinney A, Hebebrand J, et al. The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. Journal of Neural Transmission. 1997; 104:1259–1266. [PubMed: 9503271]

79. Heiming RS, Bodden C, Jansen F, Lewejohann L, Kaiser S, Lesch KP, et al. Living in a dangerous world decreases maternal care: a study in serotonin transporter knockout mice. Horm Behav. 2011; 60:397–407. [PubMed: 21787775]

80. Carola V, Gross C. Mouse Models of the 5-HTTLPR x Stress Risk Factor for Depression. Curr Top Behav Neurosci. 2012; 12:59–72. [PubMed: 22331694]

81. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A. 1998; 95:14476–14481. [PubMed: 9826725]

82. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003; 301:805–809. [PubMed: 12907793]

83. Donaldson ZR, Piel DA, Santos TL, Richardson-Jones J, Leonardo ED, Beck SG, et al. Developmental Effects of Serotonin 1A Autoreceptors on Anxiety and Social behavior. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013

84. Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron. 2010; 65:40–52. [PubMed: 20152112]

85. Bortolozzi A, Castane A, Semakova J, Santana N, Alvarado G, Cortes R, et al. New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptors. Molecular Psychiatry. 2012; 17:567. [PubMed: 22617870]

86. Albert PR. Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. Philos Trans R Soc Lond B Biol Sci. 2012; 367:2402–2415. [PubMed: 22826341]

87. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. Journal of Neuroscience. 2003; 23:8788–8799. [PubMed: 14507979]

88. Parsey RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, et al. Higher serotonin 1A binding in a second major depression cohort: Modeling and reference region considerations. Biological Psychiatry. 2010; 68:170–178. [PubMed: 20497898]